Zummo Jacqueline 4

What Happened
Jacqueline Zummo, Chief Research & Development Officer at Protara Therapeutics (TARA), sold 1,134 shares of common stock on April 8, 2026. The shares were sold at $5.40 per share for total gross proceeds of $6,124. This was a sale (not a purchase); sales are often routine and do not necessarily indicate a change in insider sentiment.

Key Details

• Transaction date: 2026-04-08; Price: $5.40 per share; Shares sold: 1,134; Gross proceeds: $6,124.
• Transaction type: Sale (code S) — open market or private sale as reported.
• Shares owned after the transaction: Not disclosed in the provided filing.
• Footnote: The sale occurred automatically under a Rule 10b5-1 trading plan established by Ms. Zummo on December 31, 2025.
• Filing timeliness: Form 4 filed Apr 9, 2026 reporting the Apr 8 transaction — appears timely.

Context: The 10b5-1 plan note means the sale was preplanned and executed under an automated schedule, which is common for insiders who want to avoid trading based on material nonpublic information. As with all insider sales, this is factual reporting of a transaction and should not be taken alone as a signal of company performance.